Virucidal benefits of povidone-iodine use on the ocular surface: a review
Open Access
- 4 August 2020
- journal article
- review article
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 5 (1), e000509
- https://doi.org/10.1136/bmjophth-2020-000509
Abstract
Povidone-iodine (PVI) preparations are well known for their microbicidal effect. In ophthalmology, PVI is commonly used to sterilise the ocular surface prior to surgical procedures. It is also used uncommonly as treatment for adenoviral conjunctivitis, yet the virucidal benefits of PVI have not been clearly documented in existing clinical management guidelines for ocular surface conditions. The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has challenged traditional healthcare systems. The morbidity and mortality of this highly contagious disease have resulted in fatalities among healthcare workers, including ophthalmologists. The SARS-CoV-2 virus has been identified on conjunctival testing, a potential source of contagious infection which may be unrecognised in asymptomatic carriers. Concern has been raised that ocular procedures may be ‘aerosol-generating’ and the additional wearing of personal protective equipment has been recommended to protect operating theatre staff. This literature review demonstrates that PVI has a broad virucidal activity, including against coronaviruses. It is already used perioperatively as standard of ophthalmic care and has been shown clinically to be effective against adenoviruses on the ocular surface. The current surgical practice of application of 5%–10% PVI applied periocularly for 3 min seems to provide an adequate effective reduction in the patient’s ocular surface viral load. The virucidal benefits of routine PVI use should be included in ophthalmology guidelines regarding safe ocular surgery protocols.Keywords
This publication has 62 references indexed in Scilit:
- Treatment of Epidemic Keratoconjunctivitis with 2% Povidone–Iodine: A Pilot StudyJournal of Ocular Pharmacology and Therapeutics, 2012
- Clinical and Antiviral Efficacy of an Ophthalmic Formulation of Dexamethasone Povidone-Iodine in a Rabbit Model of Adenoviral KeratoconjunctivitisInvestigative Opthalmology & Visual Science, 2011
- Virucidal efficacy of povidone-iodine-containing disinfectantsLetters in Applied Microbiology, 2010
- Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activitiesVirology Journal, 2009
- Nosocomial adenovirus keratoconjunctivitisBritish Journal of Ophthalmology, 2008
- Outbreak of Highly Pathogenic Avian Influenza in Japan and Anti-Influenza Virus Activity of Povidone-Iodine ProductsDermatology, 2006
- CORRECTIONBritish Journal of Ophthalmology, 2004
- The severe acute respiratory syndrome coronavirus in tearsBritish Journal of Ophthalmology, 2004
- Molecular Effects of Povidone-Iodine on Relevant Microorganisms: An Electron-Microscopic and Biochemical StudyDermatology, 1997
- Inactivation of Papillomavirus by Low Concentrations of Povidone-IodineSexually Transmitted Diseases, 1995